Volume 30, Issue 2 (June 2026)
Physiol Pharmacol 2026, 30(2): 148-158 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Shiva A, Ghasempour M, Asghari R, Hatamkhani S. Preventive effect of L-Carnitine on chemotherapyinduced oral mucositis: A randomized controlled
clinical trial. Physiol Pharmacol 2026; 30 (2) :148-158
URL: http://ppj.phypha.ir/article-1-2467-en.html
URL: http://ppj.phypha.ir/article-1-2467-en.html
Abstract: (1648 Views)
Introduction: Mucositis is acute oral toxicity induced by radiation or systemic cytotoxic chemotherapy agents in patients with cancer that may lead to discontinuing the treatment or reducing the administered dose. In this study, we aimed to evaluate the preventive effect of oral L-carnitine on chemotherapy-induced mucositis.
Methods: This prospective clinical trial employed a double-blind, randomized, placebocontrolled design. All consecutive cancer patients who met the inclusion criteria were enrolled in the oncology ward of Imam Khomeini Hospital, Urmia, Iran. Patients were randomly allocated to one of two groups: one receiving L-Carnitine 1000 mg three times daily (total dose 3000 mg/day) and the other receiving a placebo. Mucositis severity was evaluated clinically using the WHO scoring system every week throughout the 21-day study period.
Results: L-carnitine supplementation did not significantly reduce the incidence of mucositis compared to placebo (p-value = 0.748). Among the 40 enrolled patients, 20 (50%) developed mucositis: 9/16 (56.25%) in the L-carnitine group and 11/24 (45.83%) in the placebo group. Grade 2 mucositis was the most common presentation, affecting 31.3% (5/16) of the L-carnitine group and 29.2% (7/24) of the placebo group.
Conclusion: Our investigation did not identify a statistically significant impact of L-Carnitine supplementation on the incidence, severity progression, or WHO grade distribution of chemotherapy-induced oral mucositis compared to the placebo group.
Type of Manuscript: Clinical research article |
Subject:
Pharmacokinetics/Dynamics
References
1. Ana G S, Normando A G C, de Toledo I P, Dos Reis P E D, Guerra E N S. Topical treatment of oral mucositis in cancer patients: a systematic review of randomized clinical trials. Asian Pacific Journal of Cancer Prevention 2020; 21: 1851. [DOI:10.31557/APJCP.2020.21.7.1851]
2. Askarpour M, Djafarian K, Ghaedi E, Sadeghi O, Sheikhi A, Shab-Bidar S. Effect of L-Carnitine supplementation on liver enzymes: a systematic review and meta-analysis of randomized controlled trials. Archives of Medical Research 2020; 51: 82-94. [DOI:10.1016/j.arcmed.2019.12.005]
3. Babicova A, Havlínová Z, Hroch M, Rezacova M, Pejchal J, Vávrová J, et al. In vivo study of radioprotective effect of NO-synthase inhibitors and acetyl-L-carnitine. Physiological Research 2013; 62: 701. [DOI:10.33549/physiolres.932541]
4. Chaveli-López B. Oral toxicity produced by chemotherapy: A systematic review. Journal of Clinical and Experimental Dentistry 2014; 6: 81-90. [DOI:10.4317/jced.51337]
5. Cruciani R A, Dvorkin E, Homel P, Malamud S, Culliney B, Lapin J, et al. Safety, tolerability and symptom outcomes associated with L-carnitine supplementation in patients with cancer, fatigue, and carnitine deficiency: a phase I/II study. Journal of Pain and Symptom Management 2006; 32: 551-559. [DOI:10.1016/j.jpainsymman.2006.09.001]
6. Cruciani R A, Zhang J J, Manola J, Cella D, Ansari B, Fisch M J. L-carnitine supplementation for the management of fatigue in patients with cancer: An Eastern Cooperative Oncology Group phase III, randomized, double-blind, placebo-controlled trial. Journal of Clinical Oncology 2012; 30: 3864-3869. [DOI:10.1200/JCO.2011.40.2180]
7. da Cruz Campos M I, Neiva Campos C, Monteiro Aarestrup F, Vieira Aarestrup B J. Oral mucositis in cancer treatment: natural history, prevention and treatment. Molecular and Clinical Oncology 2014; 2: 337-340. [DOI:10.3892/mco.2014.253]
8. Edwards M, Mohiuddin S. Biochemistry, Lipolysis.[Updated 2022 Jul 18]. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing 2023.
9. Essawy A E, El-Sayed S A, Tousson E, Abd El-gawad H S, Alhasani R H, Abd Elkader H T A E, et al. Anti-kindling effect of Ginkgo biloba leaf extract and L-carnitine in the pentylenetetrazol model of epilepsy. Environmental Science and Pollution Research 2022; 29(32):48573-48587. [DOI:10.1007/s11356-022-19251-6]
10. Farahzadi R, Mesbah-namin S A, Zarghami N, Fathi E. L-carnitine effectively induces hTERT gene expression of human adipose tissue-derived mesenchymal stem cells obtained from the aged subjects. International Journal of Stem Cells 2016; 9: 107-114. [DOI:10.15283/ijsc.2016.9.1.107]
11. Fitzmaurice S D, Sivamani R K, Isseroff R R. Antioxidant therapies for wound healing: a clinical guide to currently commercially available products. Skin Pharmacology and Physiology 2011; 24: 113-126. [DOI:10.1159/000322643]
12. Flanagan J L, Simmons P A, Vehige J, Willcox M D, Garrett Q. Role of carnitine in disease. Nutrition and metabolism 2010; 7: 30. [DOI:10.1186/1743-7075-7-30]
13. Hatamkhani S, Khalili H, Karimzadeh I, Dashti-Khavidaki S, Abdollahi A, Jafari S. Carnitine for prevention of antituberculosis drug-induced hepatotoxicity: A randomized, clinical trial. Journal of Gastroenterology and Hepatology 2014; 29: 997-1004. [DOI:10.1111/jgh.12474]
14. Hosseini S, Elyasi S, Niazi Moghadam M R, Aledavood S A, Karimi G. Effect of oral silymarin administration on prevention of radiotherapy induced mucositis: A randomized, double-blinded, placebo-controlled clinical trial. Phytotherapy Research 2016; 27: 1879-1885. [DOI:10.1002/ptr.5704]
15. Kaźmierczak-Siedlecka K, Bulman N, Ulasiński P, Sobocki B K, Połom K, Marano L, et al. Pharmacomicrobiomics of cell-cycle specific anti-cancer drugs-is it a new perspective for personalized treatment of cancer patients? Gut Microbes 2023; 15: 2281017. [DOI:10.1080/19490976.2023.2281017]
16. Köklü A H K, Akkol E K, Kutluay Köklü A H, Küpeli Akkol E, Uğar Çankal D A, Köklü A H K, et al. Biochemical and biomechanical assessment of effects of l-carnitine on oral mucosal wounds. Clinical Oral Investigations 2015; 19: 1101-1106. [DOI:10.1007/s00784-014-1329-8]
17. Lalla R V, Bowen J, Barasch A, Elting L, Epstein J, Keefe D M, et al. MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer 2014; 120: 1453-1461. [DOI:10.1002/cncr.28592]
18. Marx W, Teleni L, Opie R S, Kelly J, Marshall S, Itsiopoulos C, et al. Efficacy and effectiveness of carnitine supplementation for cancer-related fatigue: a systematic literature review and meta-analysis. Nutrients 2017; 9: 1224. [DOI:10.3390/nu9111224]
19. Matsui H, Einama T, Shichi S, Kanazawa R, Shibuya K, Suzuki T, et al. L-Carnitine supplementation reduces the general fatigue of cancer patients during chemotherapy. Molecular and Clinical Oncology 2018; 8: 413-416. [DOI:10.3892/mco.2018.1557]
20. Mayes P A, Botham K M. Lipids of physiologic significance. A LANGE Medical Book 2000; 24: 146-157.
21. Naidu M U R, Ramana G V, Rani P U, Suman A, Roy P. Chemotherapy-induced and/or radiation therapy-induced oral mucositis-complicating the treatment of cancer. Neoplasia 2004; 6: 423-431. [DOI:10.1593/neo.04169]
22. Naranjo C A, Busto U, Sellers E M, Sandor P, Ruiz I, Roberts E A, et al. A method for estimating the probability of adverse drug reactions. Clinical Pharmacology & Therapeutics 1981; 30: 239-245. [DOI:10.1038/clpt.1981.154]
23. Ngeow W C, Chai W L, Zain R B. Management of radiation therapy-induced mucositis in head and neck cancer patients. Part I: Clinical significance, pathophysiology and prevention. Oncology Reviews 2008; 2: 102-113. [DOI:10.1007/s12156-008-0064-2]
24. Nguyen H, Sangha S, Pan M, Shin D H, Park H, Mohammed A I, et al. Oxidative stress and chemoradiation-induced oral mucositis: a scoping review of in vitro, in vivo and clinical studies. International Journal of Molecular Sciences 2022; 23: 4863. [DOI:10.3390/ijms23094863]
25. Peterson D E, Bensadoun R-J, Roila F. Management of oral and gastrointestinal mucositis: ESMO Clinical Practice Guidelines. Annals of Oncology 2011; 22: 78-84. [DOI:10.1093/annonc/mdr391]
26. Pham V H, Nguyen Q, Luu V T. Resistance (ISAAR 2015). 2015; 45: S59-S143. [DOI:10.1016/S0924-8579(15)30006-6]
27. Sangavi R, Pandiyan I. Unveiling the multifaceted management of oral mucositis in cancer patients: a narrative review. Cureus 2024; 16: 55213
28. Śledzińska A, Śledzińska P, Bebyn M, Komisarek O. Chemotherapy-induced oral complications and prophylaxis strategies. Cancer Investigation 2023; 41: 432-455. [DOI:10.1080/07357907.2023.2188558]
29. Sonis S T. The pathobiology of mucositis. Nature Reviews Cancer 2004; 20: 277-284. [DOI:10.1038/nrc1318]
30. Sonis S T, Elting L S, Keefe D, Peterson D E, Schubert M, Hauer-Jensen M, et al. Perspectives on cancer therapy-induced mucosal injury. Cancer 2004; 100: 1995-2025. [DOI:10.1002/cncr.20162]
31. Thal L J, Carta A, Clarke W R, Ferris S H, Friedland R P, Petersen R C, et al. A 1-year multicenter placebo-controlled study of acetyl-L-carnitine in patients with Alzheimer's disease. Neurology 1996; 47: 705-711. [DOI:10.1212/WNL.47.3.705]
32. Üçüncü H, Ertekin M V, Yörük Ö, Sezen O, Özkan A, Erdoğan F, et al. Vitamin E and L-carnitine, separately or in combination, in the prevention of radiation-induced oral mucositis and myelosuppression: a controlled study in a rat model. Journal of Radiation Research 2006; 47: 91-102. [DOI:10.1269/jrr.47.91]
33. Wilkes J D. Prevention and treatment of oral mucositis following cancer chemotherapy. Seminars in Oncology 1998; 25: 538-551.
34. Wong H M. Oral complications and management strategies for patients undergoing cancer therapy. The Scientific World Journal 2014; 2014: 581795. [DOI:10.1155/2014/581795]
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
